{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:20:35Z","timestamp":1791778835933,"version":"4.3.4"},"reference-count":46,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2011,2,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Seventy-six subjects with untreated DLBCL (n = 40) and MCL (n = 36) received standard CHOP every 21 days (CHOP-21) with R plus bortezomib at 0.7 mg\/m<jats:sup>2<\/jats:sup>(n = 4), 1.0 mg\/m<jats:sup>2<\/jats:sup>(n = 9), or 1.3 mg\/m<jats:sup>2<\/jats:sup>(n = 63) on days 1 and 4 for six cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median age was 63 years (range, 20 to 87), and International Prognostic Index (IPI) scores were generally unfavorable (39% with IPI of 2, and 49% with IPI of 3 to 5), as were Mantle Cell Lymphoma International Prognostic Index scores in patients with MCL (28% intermediate risk and 39% high risk). Toxicity was manageable, including neuropathy in 49 subjects (8% grade 2 and 4% grade 3) and grade 3\/4 anemia (13%), neutropenia (41%), and thrombocytopenia (25%). For DLBCL, the evaluable overall response rate (ORR) was 100% with 86% complete response (CR)\/CR unconfirmed (CRu; n = 35). Intent-to-treat (ITT, n = 40) ORR was 88% with 75% CR\/CRu, 2-year progression-free survival (PFS) of 64% (95% CI, 47% to 77%) and 2-year overall survival (OS) of 70% (95% CI, 53% to 82%). For MCL, the evaluable ORR was 91% with 72% CR\/CRu (n = 32). The ITT (n = 36) ORR was 81% with 64% CR\/CRu, 2-year PFS 44% (95% CI, 27% to 60%) and 2-year OS 86% (95% CI, 70% to 94%). IPI and MIPI correlated with survival in DLBCL and MCL, respectively. Unlike in DLBCL treated with R-CHOP alone, nongerminal center B cell (non-GCB) and GCB subtypes had similar outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Bortezomib with R-CHOP-21 can be safely administered and may enhance outcomes, particularly in non-GCB DLBCL, justifying randomized studies.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2010.31.1142","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T01:59:19Z","timestamp":1293587959000},"page":"690-697","source":"Crossref","is-referenced-by-count":270,"title":["Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma"],"prefix":"10.1200","volume":"29","author":[{"given":"Jia","family":"Ruan","sequence":"first","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing M.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Cheung","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Morrison","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Elstrom","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ely","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chadburn","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Cesarman","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Mailman School of Public Health, Columbia University, New York, NY; University of Nebraska Medical Center, Omaha, NE; and the Dana-Farber Cancer Institute, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(03)00119-2","volume":"30","author":"Fisher RI","year":"2003","journal-title":"Semin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.12.003"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-29346-2_5"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.015"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-68"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802885"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1391"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804295105"},{"key":"B18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","volume":"11","author":"Lam LT","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1861"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"B23","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling M","year":"2005","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199679"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25509"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2307\/2531628"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.01177.x"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1204"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.296"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.265.265","volume":"112","author":"Kahl B","year":"2008","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1661.1661"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.31.1142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T16:56:52Z","timestamp":1685897812000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.31.1142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,20]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,2,20]]}},"alternative-id":["10.1200\/JCO.2010.31.1142"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.31.1142","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,20]]}}}